New treatment for viral arthritis reveals impressive results in Phase 2 human clinical trial
Griffith University's Institute for Glycomics and Melbourne-based company Paradigm Biopharmaceuticals Limited (ASX: PAR) have reported impressive results from their Phase 2A clinical trials of a new drug candidate to treat ...
Dec 13, 2019
0
0